sars cov 2 — grants

Sort

8,912 grants matching “sars cov 2”

Molecular Basis of Allergic and Immunologic Disease

$717,923

Hans C. Oettgen · Boston Children'S Hospital · T32 · FY2025 · AI

CASP-11-dependent RNA modifications and their Role in Multi-Organ Pathologies

$717,804

Jianrong Li · Ohio State University · P01 · FY2024 · AI

Highly Selective Pathogen Inactivators For Treatment of Convalescent Transfusion Plasma

$717,598

David R Tabatadze · Zata Pharmaceuticals, Inc. · R43 · FY2021 · HL

Isolation of bioactive proteins from natural product extracts

$717,581

Barry Okeefe · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Advancing the development of a novel class of small molecules for treating pan-coronavirus infections

$717,555

Shirit Einav · Stanford University · R01 · FY2025 · AI

COVID-19 shutdown: impact of healthcare disruptions on cardiovascular health disparities among people with multiple chronic conditions in New York City.

$716,579

John A Dodson · New York University School Of Medicine · R01 · FY2022 · AG

Pneumonia Biology

$716,519

Joseph P Mizgerd · Boston University Medical Campus · R35 · FY2020 · HL

The longer-term impact of prenatal exposure to SARS-CoV-2 infection and the COVID-19 vaccine on behavior, cognition, and brain functioning in the child

$716,474

Anna-Sophie Rommel · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · HD

Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

$716,336

Jeffrey Andrew Sparks · Brigham And Women'S Hospital · R01 · FY2024 · AR

iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells

$715,989

Jalees Rehman · University Of Illinois At Chicago · R01 · FY2024 · HL

Connecting our Neighborhoods Need for Enhanced and Coordinated Testing to Achieve Equity: CoNNECT to Achieve Equality

$715,920

Pearl McElfish · Univ Of Arkansas For Med Scis · R01 · FY2021 · MD

Involvement Of Human Viruses Associated With Chronic Neurologic Disease

$715,738

Steven Jacobson · National Institute Of Neurological Disorders And Stroke · ZIA · FY2025 · NS

Leveraging community health workers to improve SARS-CoV-2 testing and mitigation among criminal justice-involved individuals accessing a corrections-focused community-based organization

$715,734

Matthew Akiyama · Albert Einstein College Of Medicine · R01 · FY2022 · MD

Research Project 2 The pregnancy AdaptOME

$715,267

Boris Dominik Juelg · Massachusetts Institute Of Technology · U19 · FY2024 · AI

COVID-19 Pandemic Mitigation, Community Economic and Social Vulnerability, and Opioid Use Disorder

$714,815

Elaine L Hill · University Of Rochester · U01 · FY2023 · DA

Surveillance of SARS-CoV-2 Variants in Hawaii

$714,791

Robert Alan Nichols · University Of Hawaii At Manoa · P20 · FY2021 · GM

Natural Killer cells and the Immunogenetics of COVID-19

$714,785

Paul John Norman · University Of Colorado Denver · R01 · FY2022 · AI

Natural Killer cells and the Immunogenetics of COVID-19

$714,601

Paul John Norman · University Of Colorado Denver · R01 · FY2023 · AI

Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2

$714,282

Anne Moscona · Columbia University Health Sciences · R01 · FY2024 · AI

Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses

$714,193

David Michael Markovitz · University Of Michigan At Ann Arbor · R01 · FY2025 · AI

Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses

$714,193

David Michael Markovitz · University Of Michigan At Ann Arbor · R01 · FY2024 · AI

Fusion inhibitors that block host-to-host transmission of SARS-CoV-2

$714,110

Matteo Porotto · Columbia University Health Sciences · R01 · FY2023 · AI

Molecular Basis of Allergic and Immunologic Disease

CASP-11-dependent RNA modifications and their Role in Multi-Organ Pathologies

Highly Selective Pathogen Inactivators For Treatment of Convalescent Transfusion Plasma

Isolation of bioactive proteins from natural product extracts

Advancing the development of a novel class of small molecules for treating pan-coronavirus infections

MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION

Mechanisms of lung and cardiac pathology in SARS-CoV-2 infections

Fusion inhibitors that block host-to-host transmission of SARS-CoV-2

COVID-19 shutdown: impact of healthcare disruptions on cardiovascular health disparities among people with multiple chronic conditions in New York City.

Pneumonia Biology

The longer-term impact of prenatal exposure to SARS-CoV-2 infection and the COVID-19 vaccine on behavior, cognition, and brain functioning in the child

Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells

Connecting our Neighborhoods Need for Enhanced and Coordinated Testing to Achieve Equity: CoNNECT to Achieve Equality

Involvement Of Human Viruses Associated With Chronic Neurologic Disease

Leveraging community health workers to improve SARS-CoV-2 testing and mitigation among criminal justice-involved individuals accessing a corrections-focused community-based organization

Research Project 2 The pregnancy AdaptOME

COVID-19 Pandemic Mitigation, Community Economic and Social Vulnerability, and Opioid Use Disorder

Surveillance of SARS-CoV-2 Variants in Hawaii

Natural Killer cells and the Immunogenetics of COVID-19

Natural Killer cells and the Immunogenetics of COVID-19

Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2

Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses

Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses

Fusion inhibitors that block host-to-host transmission of SARS-CoV-2